Sanofi (NASDAQ:SNY) Shares Sold by Hilltop National Bank

Hilltop National Bank reduced its stake in Sanofi (NASDAQ:SNY) by 4.0% during the 4th quarter, Holdings Channel reports. The institutional investor owned 11,377 shares of the company’s stock after selling 472 shares during the period. Hilltop National Bank’s holdings in Sanofi were worth $549,000 at the end of the most recent quarter.

A number of other large investors also recently bought and sold shares of SNY. Stablepoint Partners LLC raised its holdings in shares of Sanofi by 0.8% in the 3rd quarter. Stablepoint Partners LLC now owns 23,893 shares of the company’s stock valued at $1,377,000 after buying an additional 189 shares during the period. PDS Planning Inc grew its position in Sanofi by 3.1% in the 3rd quarter. PDS Planning Inc now owns 6,643 shares of the company’s stock valued at $383,000 after acquiring an additional 200 shares in the last quarter. Eagle Ridge Investment Management increased its stake in Sanofi by 3.8% during the third quarter. Eagle Ridge Investment Management now owns 5,571 shares of the company’s stock worth $321,000 after purchasing an additional 203 shares during the period. Financial Advocates Investment Management lifted its position in shares of Sanofi by 3.4% during the third quarter. Financial Advocates Investment Management now owns 6,327 shares of the company’s stock worth $365,000 after purchasing an additional 206 shares in the last quarter. Finally, Angeles Investment Advisors LLC boosted its stake in shares of Sanofi by 1.9% in the third quarter. Angeles Investment Advisors LLC now owns 11,323 shares of the company’s stock valued at $653,000 after purchasing an additional 210 shares during the period. Institutional investors and hedge funds own 14.04% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have issued reports on SNY. StockNews.com lowered shares of Sanofi from a “buy” rating to a “hold” rating in a report on Thursday, December 12th. Citigroup upgraded Sanofi to a “strong-buy” rating in a research note on Tuesday, September 17th. Two analysts have rated the stock with a hold rating, one has given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $57.50.

Sanofi Stock Down 0.5 %

NASDAQ:SNY traded down $0.26 during mid-day trading on Friday, hitting $48.97. The stock had a trading volume of 602,779 shares, compared to its average volume of 1,990,278. Sanofi has a twelve month low of $45.22 and a twelve month high of $58.97. The stock has a 50-day simple moving average of $48.79 and a two-hundred day simple moving average of $52.07. The company has a current ratio of 1.00, a quick ratio of 0.65 and a debt-to-equity ratio of 0.17. The company has a market capitalization of $124.28 billion, a PE ratio of 24.98, a PEG ratio of 1.23 and a beta of 0.57.

Sanofi (NASDAQ:SNY) last announced its quarterly earnings data on Friday, October 25th. The company reported $1.57 earnings per share for the quarter, beating analysts’ consensus estimates of $0.22 by $1.35. The business had revenue of $13.44 billion for the quarter, compared to analyst estimates of $16.59 billion. Sanofi had a net margin of 9.96% and a return on equity of 27.45%. The company’s revenue was up 12.3% on a year-over-year basis. During the same period last year, the business earned $2.55 EPS. On average, equities research analysts anticipate that Sanofi will post 4.06 EPS for the current year.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.